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ABSTRACT 
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Chairperson of the Supervisory Committee:                        Dr. Caroline 
Whitacre 
                                                                                   Vice President for Research,
  Office of Research 
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system 
(CNS) which is characterized by demyelination and axonal loss when autoreactive 
T lymphocytes gain access to the CNS.  This leads to clinical symptoms of 
decreased motor and sensory functions.  Macrophage migration inhibitory factor 
(MIF) has been shown to be critical for the progression of experimental 
autoimmune encephalomyelitis (EAE), an animal model for MS.  When 
immunized with the encephalitogenic peptide of myelin oligodendrocyte 
glycoprotein (MOG) 35-55, mice deficient in the pro-inflammatory cytokine MIF 
are protected from EAE.  .   We show the clinical signs of EAE can be reversed 
by the use of small molecule inhibitors of MIF.  Yet, MIF is constitutively 
expressed in all cell types and important in innate immune function, thus global 
inhibition of MIF could potentially cause adverse side effects.  Thus, we 
investigate the cellular source of the biologically relevant MIF for EAE.   
Through a series of bone marrow chimera and adoptive transfer experiments, we 
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concluded the necessary MIF is bone marrow derived.  These experiments 
eliminated T lymphocytes as the source of the biologically relevant MIF.   
 
Recently, MIF has been linked to B lymphocyte maturation.  Although the role of 
B lymphocytes in MS pathology remains unclear, the recent success of Rituximab, 
a monoclonal antibody against human B lymphocytes, argues for a strong role of 
B lymphocytes in MS.  The purpose of the latter part of this study is to 
investigate the autocrine role of MIF production by B lymphocytes in EAE as a 
future specific therapeutic target.  We observed significantly fewer mature B 
lymphocytes in the immune compartments of MIF deficient mice when 
compared to wild type counterparts.  Yet, significantly more progenitor B 
lymphocytes were observed in an MIF deficient mice, leading to the hypothesis 
that MIF may be crucial for B lymphocyte survival.  We also observed impaired 
proliferation of B lymphocytes in the bone marrow of a MIF knockout mouse.  
Next, we performed a series of transfer experiments where the only source of 
MIF is B lymphocytes  to determine if this source alone could induce EAE; 
therefore providing a specific cell type to target MIF production in EAE.  We 
observed protection of MIF deficient recipients regardless of MIF production by 
the B lymphocytes.  Our data suggests that although MIF is important for B cell 
survival, it does not act in an autocrine manner.   
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“No can be one of the most positive words in the world.  No, I will not 
give up.  No, I will not be defeated.” 
 
 
 
 
 
This work is dedicated to my determined mother who passed away due to 
complications of MS.  She never let the disease take her positive attitude, no 
matter the challenges and falls.  She was a dedicated mother and wife whose 
lessons have shaped my approach to life. 
 
To my mother and the many other loved ones who are battling this unpredictable 
disease.  May a cure come quickly.  
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C h a p t e r  1  
INTRODUCTION AND BACKGROUND 
 
Meaning “many scars,” multiple sclerosis (MS) was named for the many lesions 
(scars) found in the brain and spinal cord of affected individuals.  The disease was 
first described by Dr. Jean Martin Charcot in the mid-1800s when he 
differentiated it from other neurological disorders by its central nervous system 
(CNS) damage.  Despite the scientific advancements made in understanding both 
the nervous and immune systems, the pathology of multiple sclerosis remains 
unknown and is an area of active research.  Yet, the disease is widely accepted as 
an autoimmune disease of the CNS.  Both the initial event causing autoimmunity 
and the subsequent events mediating its tissue damage remain poorly understood 
today.  These events must be better understood for the development of targeted 
therapies to treat the debilitating symptoms of MS.       
 
1.1 Problem Statement  
 
Though many specific aspects of MS remain unknown, inflammation is involved 
in mediating the damage seen within the CNS, which is primarily mediated by 
auto-reactive T lymphocytes  (Glass CK, 2010).  Unaffected individuals also have 
auto-reactive T lymphocytes, yet in unaffected individuals, these cells do not gain 
access to the CNS and are held in check.  Access to the CNS is prevented by the 
blood brain barrier (BBB), an extremely tight barrier of endothelial cells at the 
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interface between the periphery (blood) and the CNS (brain).  However in MS, 
the BBB is compromised, allowing the auto-reactive T lymphocytes to cross into 
the CNS, where they are activated and mediate damage.  Although the 
mechanism behind BBB damage is unknown, cytokines and adhesion molecules 
play a large role in recruiting damaging cells into the CNS.  Macrophage 
migration inhibitory factor (MIF) was first described in 1976 as a pro-
inflammatory cytokine secreted by activated T lymphocytes.  It was named for its 
ability to prevent the movement of macrophages out of a capillary tube (Bloom, 
1966 and David, 1967).  Recently, MIF has been re-evaluated as an important link 
between the innate and adaptive immune responses.  Data from our lab has 
shown that MIF is important for the progression of experimental autoimmune 
encephalomyelitis (EAE), an animal model for MS (Gold, 2000).  Thus, my 
problem statement is: to determine the specific cell type through which MIF 
mediates its pro-inflammatory effects in MS.  The ensuing chapters will 
specifically explore B lymphocytes as a candidate cell type.  
 
1.2 Multiple Sclerosis (MS) 
 
Multiple sclerosis (MS) is a disease of the central nervous system that is 
characterized by demyelination and axonal loss, leading to clinical symptoms of 
decreased motor and sensory functions (Noseworthy, 2000).  The clinical 
symptoms include muscle weakness and spasms; difficulties with coordination, 
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balance, and movement; fatigue; acute or chronic pain syndromes; and bladder 
and bowel difficulties. 
 
Although the exact mechanism of damage in MS is not well understood, it is 
generally accepted that myelin specific auto-reactive T lymphocytes gain access to 
the CNS.  Once in the CNS, the T lymphocytes are activated and together with 
other immune cells mediate functions such as antigen presentation, cytotoxicity 
effects, cytokine release, and activation of additional cells.  Not only do the 
immune cells mediate damage directly, but they also cause a generalized site of 
inflammation which expands tissue damage.  The influx of auto-reactive and 
activated immune cells is believed to result in damage to the myelin sheath 
surrounding neurons.  The inflammation and demyelination are thought to cause 
the majority of the symptoms associated with MS. More recent evidence suggests 
oligodendrocytes (myelin producing cells) and axons may be targeted in MS as 
well (Trapp, 1998). 
 
1.3 Experimental Autoimmune Encephalomyelitis (EAE) 
 
Many of the current therapies for, understanding of, and research on MS is made 
possible through utilization of the animal model experimental autoimmune 
encephalomyelitis (EAE), which mimics many of the clinical, pathological, and 
immunologic events seen in MS.  In susceptible mouse strains, EAE presents 
with ascending paralysis as activated T lymphocytes cross the BBB and infiltrate 
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the white matter of the CNS (Papenfuss, 2004). EAE is induced by immunization 
with myelin antigens together with immune stimulators known as adjuvants.  In 
the C57Bl/6 mouse strain (which is the genetic background of all mice used in 
the following study), EAE is induced by immunization with the encephalitogenic 
myelin oligodendrocyte glycoprotein (MOG) peptide. 
 
1.4 B Lymphocytes 
 
B lymphocytes are a subtype of white blood cells which are responsible for 
antibody production in the adaptive immune response.  Despite their well defined 
role in antibody production, the role of B lymphocytes in MS remains unclear.  
Support for their involvement has been shown in studies of antigen presentation, 
cytokine production, and auto-antibody production (McLaughlin, 2008).  A 
recent study by Magliozzi et al. showed that ectopic follicles containing B 
lymphocytes are found in mice with progressive relapsing EAE as well as in the 
meninges of patients with secondary-progressive MS (Magliozzi, 2007).  The 
location of these follicles suggests that B lymphocytes migrate to the CNS.  It is 
not clear  whether the B lymphocytes are activated locally where they present 
antigens, and differentiate into memory B cells, rather that they are being 
activated in the periphery and migrating to the CNS in a fully mature state 
(McLaughlin, 2008).  Other investigators have shown that antigen specific B 
lymphocytes are required to prime the pathogenic CD4+ T lymphocytes with low 
doses of antigen, similar to the levels in MS (Riveria, 2001).   
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Perhaps the most striking evidence arguing for the importance of B lymphocytes 
in MS arose from a study by Hauser et al. in which Rituximab, a monoclonal 
antibody directed against the B lymphocyte specific surface protein CD20, was 
used to treat MS patients.  The treated patients experienced significantly less 
lesion development, resulting in clinical improvement (Hauser S., 2008).  Taken 
together with the above suggested roles of B lymphocytes, this evidence revived 
the investigation of B lymphocytes in multiple sclerosis.   
 
1.5 Macrophage Migration Inhibitory Factor (MIF) 
 
The pro-inflammatory cytokine, macrophage migration inhibitory factor (MIF), 
has recently been re-discovered as an important link between innate and adaptive 
immune function (Denkinger, 2003).  MIF was found to be present in a number 
of immune cells, including monocytes, T and B lymphocytes, neutrophils, 
macrophages, dendritic cells, mast cells, and basophils.  Additionally, MIF is 
found in epithelial cells lining the lung and gastrointestinal tract, as well as in 
endothelial cells (Denkinger, 2003).  MIF is ubiquitously produced during 
inflammatory immune responses and plays a significant role in the up-regulation 
of inflammatory cytokines involved in the pathogenesis of EAE.  Importantly, 
MIF is elevated in the cerebrospinal fluid (CSF) of MS patients during relapses 
(Niino, 2000).  Our laboratory reported that MIF deficient mice show decreased 
signs of EAE compared with control mice.  Specifically, MIF knockout mice 
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show a mild acute phase of disease, but do not show progression of the disease  
(Powell N.D., 2005 and Figure 1.1).  Interestingly, MIF has been shown to be 
critical for mature B cell survival (Gore Y., 2008).  Also, recent evidence shows 
that MIF signals in an autocrine fashion (Lue H., 2007).  These results led MIF to 
be studied with an emphasis on B lymphocytes as a possible therapeutic target for 
the treatment of MS. 
 
 
1.6 MS Therapies 
 
Despite the many uncertainties with respect to MS pathogenesis, treatments are 
available and can be marginally successful for some patients.  The first wave of 
therapies focused on hormonal administration, primarily glucocorticoids.  
Glucocorticoids are a class of steroids which suppress the immune system, 
thereby lessening the autoimmune attack of MS.  Glucocorticoids can shorten 
relapses and lengthen remissions (Noseworthy J. L., 2000).  
 
The true staple of current MS therapy is beta interferon.  The interferon family of 
drugs includes Betaseron, Avonex, and Rebif.  Though these drugs have been 
shown to reduce relapses and delay the progression of MS, the mechanism of 
action is poorly understood.  Yet, they remain integral to most MS therapy plans 
(Kinkel, 2006 and Rio, 2005). 
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Newer therapies include monoclonal antibodies, such as Natalizamab and 
Rituximab.  Natalizamab is a monoclonal antibody directed against α4-integrin 
which is a critical mediator of leukocyte entry into tissue (Polman, 2006 and 
Rudick, 2006).  Unfortunately, its administration has been linked to an increased 
risk of progressive multifocal luekencephalopathy with an estimated incidence of 
1 in 1000 treated patients (Yousry, 2006 and Hartung, 2009).  Rituximab, a 
monoclonal antibody directed against CD20, has shown promising results in 
clinical trials.  This evidence provides a solid foundation for the re-examination of 
B lymphocytes in MS pathology. 
 
Despite the number of current therapies, a cure or holistic treatment remains 
absent from MS therapy options.  Research continues to search for a targeted 
therapy which leaves the remaining immune system intact and effective to fight 
opportunistic infections, while quieting the autoimmune attack of MS.    
     
1.7 Significance and Objectives 
 
MS is the most common demyelinating disease of the CNS.  Presently, the 
etiology is unknown but the presumed mechanism is autoimmune as 
demonstrated by the presence of autoreactive myelin specific T lymphocytes in 
the CNS.  Currently, no treatment has proven curative; however, B lymphocyte 
depletion therapies such as Rituximab have proven beneficial.   Understanding 
the role of B lymphocytes and MIF production in EAE pathogenesis will be 
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significant for the treatment of MS as both appear to play a vital role in disease 
progression.  Several small molecule inhibitors for MIF are available, however if 
the target could be further narrowed to MIF producing B lymphocytes through 
the use of a small interfering RNA (siRNA) for example, fewer side effects would 
accompany the treatment. 
  
 9 
 
Wild- type
Knockout
Figure 1.1: The genetic deletion of MIF is protective against EAE.
Wild type (   , n=18) and MIF ko (    , n=13) mice were immunized for EAE 
with 200 μg MOG(35-55) peptide in adjuvant.  MIF ko mice are protected 
from the progression of EAE and exhibit less severe EAE relative to wild-
type controls.  Data are representative of four separate experiments.
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*This work was completed by Aaron P. Kithcart, PhD.
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C h a p t e r  2  
METHODS 
2.1 Mice  
Male C57Bl/6 wild-type mice were purchased from Jackson Laboratories (Bar 
Harbor, Maine, USA) and housed five per unit in standard ventilated cages.  
Age- matched male C57Bl/6 recombination activating gene (RAG) 2 knockout 
mice were purchased from Taconic and bred in house (The Ohio State 
University).  MIF deficient mice were developed as previously described 
(Bozza, 1999). 
 
All mice were allowed a seven-day acclimation period prior to any experimental 
procedures and were between six and eight weeks of age at the time of use. 
Mice were cared for according to policies established by The Ohio State 
University and housed in the vivarium in the Biomedical Research Tower. Mice 
were maintained on a 12-hour light/dark cycle with lights on at 0600 h and off 
at 1800 h. Food and water were given ad libitum. Mice were randomly assigned 
to experimental groups and ear tagged for identification purposes. 
 
2.2 Antigens 
Myelin oligodendrocyte glycoprotein (MOG) 35-55 (MEVGWYRSPFSRVV 
 11 
 
HLYRNGK) peptide used for the induction of EAE in C57Bl/6 mice and was 
purchased from Princeton Biomolecules Corporation (Langhorne, 
Pennsylvania, USA). This peptide was purified by high performance liquid 
chromatography (HPLC) and had a purity of greater than 90 percent.  
 
2.3 Cell Purification 
CD4+ T lymphocytes were purified by the negative selection using a magnetic 
bead kit from Miltenyi Biotec (Bergisch Gladbach, Germany). Single cell 
suspensions were depleted of non-CD4 cells using anti-CD8α, -CD11b, -
CD45R, -CD49b, and -Ter-119 monoclonal antibodies conjugated to biotin. 
Anti-biotin microbeads were used to magnetically separate the antibody-labeled 
cells.  Purity, confirmed by flow cytometry, was greater than 95%.  
 
B lymphocytes were also purified by the negative selection using a magnetic 
bead kit from Miltenyi Biotec (Bergisch Gladbach, Germany). Single cell 
suspensions were depleted of non-B220+ B cells using anti- CD8α, -CD11b, -
CD4, -CD43, and -Ter-119 monoclonal antibodies directly conjugated to biotin. 
Anti-biotin microbeads were used to magnetically separate the antibody-labeled 
cells.  Purity, confirmed by flow cytometry, was greater than 90%. 
Purified splenocytes were cultured at 4x105 cells per well in a 96 well culture 
plate.  Media was supplemented with 2 μg/ml anti-CD3. 
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2.4 Induction of Experimental Autoimmune Encephalomyelitis 
For the induction of EAE in wild type mice, the mice were immunized with 
200 μg MOG (35-55) peptide (Princeton Biomolecules) emulsified in complete 
Freund’s adjuvant (containing 200 μg Mycobacterium tuberculosis Jamaica strain).  
The emulsion was injected intradermally in each of four flanks.  Pertussis toxin 
(List Biological Labs, Campbell, CA, USA) was injected as an additional 
adjuvant intraperitoneally (i.p.) on the day of immunization and 48 hours later 
(200 ng in 0.2 ml phosphate buffered saline). 
 
For the induction of EAE in RAG knockout mice, the mice were given purified 
CD4+ T lymphocytes from male wild type or MIF-/- donor mice.  Purity 
following the cell isolation protocol as determined by flow cytometry, was 
greater than 95 percent, and the cells were transferred into male recipient    
RAG-/- mice by intravenous (i.v.) injection in phosphate buffered saline. 
Recipient mice were immunized for EAE as described above with MOG (35-
55) peptide on the day of or two days following T lymphocyte transfer.  
 
All animals were observed daily for EAE clinical signs and scored according to 
degree of paralysis; 0 = no paralysis, 1 = limp tail or ataxia, 2 = limp tail with 
ataxia, 3 = partial hind limb paralysis, 4 = complete hind limb paralysis, and 5 = 
death. Cumulative disease index (CDI) was calculated as the sum of daily 
clinical scores from each animal during the course of observation or treatment.  
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CDI was reported as an average within each group. Peak score was reported as 
the average maximum clinical score within each group over the observed 
period.  EAE incidence was calculated based on individual animals and reported 
as a mean within each group. 
 
2.5 Transfer of Experimental Autoimmune Encephalomyelitis 
EAE was adoptively transferred following in vitro culture of splenocytes for 
some experiments. Donor male wild-type or MIF knockout mice were 
immunized as described above with MOG (35-55) peptide and adjuvants.  Ten 
days following immunization, spleens and draining lymph node cells from the 
sites of injection were isolated, dissociated into a single cell suspension, and 
placed into culture for 72 hours with RPMI 1640 medium (containing 10 
percent fetal bovine serum, 25 mM HEPES, 2 mM L-glutamine, 50 U/ml 
penicillin, 50 ug/ml streptomycin, and 5x10-5 M 2-ME) with 20 μg/ml MOG 
(35-55) peptide and 0.5 ng/ml IL-12p70 (BD Biosciences, San Jose, California, 
USA). The MOG (35-55) peptide and IL-12p70 were used to reactivate the T 
lymphocytes in vitro.  Following culture, cells were washed twice in phosphate 
buffered saline (PBS), and 10x106 cells were injected i.v. into male recipient 
mice.  
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2.6 Drug Administration 
The small molecule inhibitors of MIF (CPSI-00155S, -00155F, -00156S, gifts 
from Cytokine PharmaSciences, King of Prussia, Pennsylvania, USA) were 
administered to mice following induction of EAE. Inhibitors were given either 
i.p. or orally by gavage.  For i.p. administration, drug was dissolved in sterile 
DMSO, and then diluted in PBS for an overall ratio of 1:3 (DMSO to PBS). 
The concentration of inhibitor dissolved was based on overall dosing 
requirements and the total volume administered was 50 μl. Orally administered 
inhibitor was dissolved in 15 percent DMSO in 0.1 percent methylcellulose in 
water. Mice were fed a total of 50 μl at a given concentration of inhibitor by 
gavage. Vehicle controls received 15 percent DMSO in 0.1 percent 
methylcellulose and were included in all experiments. The time of day of 
inhibitor administration was kept constant, between 1000 h and 1200 h.   
 
2.7 Generation of Bone Marrow Chimeras 
Male donor wild-type or MIF-/- mice were euthanized, and the femur, tibia, and 
humerus from each mouse were collected aseptically. Bone marrow was flushed 
from the medullary cavity with supplemented RPMI 1640 using an 18-gauge 
needle and syringe. The immune system of recipient RAG-/- or MIF-/-x RAG-/- 
mice was ablated by irradiation using a Gammacell GC40 irradiator (MDS 
Norion, Ottawa, ON, Canada) at 350 rads, followed by a second 
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dose of 350 rads two hours later.  A single cell suspension of 10x106 bone 
marrow cells in PBS was transferred i.v. into recipient mice immediately 
following irradiation. Water was supplemented with 0.2 percent enrofloxacin 
(Baytril, Shawnee Mission, Kansas, USA) to prevent infection for two weeks 
following irradiation. 
 
To verify immune reconstitution, at six weeks post-irradiation, blood was 
drawn from the submandibular vessel bed using a sterile lancet and analyzed by 
flow cytometry for the presence of CD4+ T and CD19+ B lymphocytes. 
 
2.8 Flow Cytometry 
Single cell suspensions from draining lymph nodes, spleens, and bone marrow  
were stained with anti-B220, -CD4, -CD25, -CD19, -CD80, -CD86, -IgM, or     
-IgD fluorescein isothiocyanate (FITC)-, phycoerythrin(PE)-, allophycocyanin 
(APC)-, or pacific blue-conjugated fluorescent antibodies (BD Biosciences).  
Isotype control monoclonal antibodies (BD Biosciences) were matched for 
each fluorochrome. Cells were labeled at 1x106 cells per tube, incubated for 20 
minutes at 4°C, and measured using a FACSCalibur flow cytometer (BD 
Biosciences). Analysis was performed on a FACSCanto II flow cytometer and 
analyzed using Diva software (both from BD Biosciences). 
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2.9 CFSE Proliferation Assay 
Single cell suspensions from the organs of interest from donor mice were purified 
for CD4+ T lymphocytes using magnetic separation described previously.  The 
purified cells were then washed with 5 percent FBS in PBS.  CFSE was added to 
a final concentration of 5 μM.  The staining cells were cultured at room 
temperature in the dark for seven minutes.  The CFSE cell solution was then 
diluted to 50x its volume with 5 percent FBS in PBS and washed three times.  
CFSE staining was confirmed by flow cytometry. 
The cells were either transferred i.v. into recipient mice as described above or 
were placed into culture.  At the specified time point, the CFSE stained cells were 
recovered and analyzed using flow cytometry.  If they were transferred in vivo, the 
recipient mouse was sacrificed and single cell suspensions were derived from the 
organs of interest.  Proliferating cells were denoted by discrete peaks shifted to 
the left in the flow cytometric histogram. 
2.10 Immunohistochemical Staining 
Samples were prepared by removing brains and spinal cords post immunization.  
The organs were flash frozen at -80°C in OCT media.  Antibody staining for 
CD4+ T lymphocytes was performed by The Ohio State University Veterinary 
Sciences core facility.    
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C h a p t e r  3  
A SMALL MOLECULE INHIBITOR OF MIF CAN REVERSE EAE 
CLINICAL SIGNS 
MIF is a key mediator in EAE pathogenesis as evidenced by the reduced  disease 
severity observed in MIF deficient mice (Figure 1.1).  Other cytokines, including 
IFNγ and IL-17, have also been investigated as possible therapeutic targets 
(Panitch, 1987 and  Tzartos, 2008).  Our laboratory has shown a definite role for 
MIF in EAE progression using different mouse strains and immunization 
regimens which result in both chronic and relapsing-remitting EAE.  In this 
chapter, we will explore MIF as a therapeutic target by exploring the efficacy of 
two small molecule inhibitors.  The route of administration  of the inhibitors, 
either orally or intraperitoneally, will also be explored, since no established oral 
therapy is currently available for the treatment of MS. 
3.1 A Small Molecule Inhibitor of MIF Reduces Ongoing EAE  
To this point, we had explored mice genetically lacking MIF to wild-type 
controls.  MIF deficient mice experience less severe EAE with very little 
progression of disease compared to wild-type mice (Figure 1.1).  We now sought 
to explore MIF as a possible therapeutic target by the use of a small molecule 
inhibitor.  Ongoing EAE was targeted because the differences in clinical severity 
between MIF deficient and wild-type mice were greatest during the progression 
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of EAE.  Additionally, ongoing EAE represents the most clinically relevant time 
point, as it is after diagnosis and when therapy would begin for a patient.   
Two small molecule inhibitors of MIF, CPSI-00155F and CPSI-00155S were 
obtained through collaboration with Cytokine PharmaSciences.  The two 
different inhibitors have the same chemical composition but differing 
stereochemistry.  Both disrupt the tertiary structure of MIF, preventing both its 
ligand binding and enzymatic functions.  We explored the effectiveness of the 
inhibitors to reduce ongoing EAE.  Additionally, the efficacy differences between 
the two inhibitors were explored (Figure 3.1).  Wild-type C57Bl/6 mice were 
immunized for EAE with 200 μg MOG (35-55) peptide.  Seventeen days later 
during the peak of the induction phase, mice in the treated group were given 10.0 
mg/kg i.p. of the inhibitor daily for fourteen consecutive days.  Vehicle controls 
were given 25 percent DMSO in 0.5 percent methylcellulose daily for the same 
fourteen days as the inhibitor.  Mice receiving the CPSI-00155F inhibitor 
exhibited reduced severity of EAE as soon as four days after inhibitor treatment 
began.  Mice in the CPSI-00155F inhibitor treated group had a reduced 
cumulative disease index (CDI) relative to both CPSI-00155S treated mice and 
vehicle controls (7.50 compared to 10.36 and 11.82, respectively; p<0.05, Table 
3.1).  Additionally, the mice in the CPSI-00155F inhibitor treated group followed 
a trend of a lower mean score relative to both (0.47 compared to 0.78 for the 
CPSI-00155S treated mice and 0.65 for the vehicle treated mice, Table 3.1).  We 
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concluded that a small molecule inhibitor of MIF can be therapeutic when 
administered during ongoing EAE. 
3.2 CPSI-00155S is Not as Effective Given Orally 
No oral therapies are currently approved for multiple sclerosis treatment; 
however, research is advancing in this area with the recent positive results from 
two large-scale phase III clinical trials for oral Fingolimod.  Administration of 
Fingolimod was shown to significantly reduce the frequency of MS relapses and 
may slow progression.  The desirability of an oral treatment led us to explore the 
oral effectiveness of two different small molecule inhibitors of MIF from 
Cytokine Pharmasciences. 
First, CPSI-00155F and S were tested for oral administration after observing the 
effectiveness of CSPI-00155F when administered i.p. (Figure 3.2).  Wild-type 
C57Bl/6 mice were immunized for EAE with 200 μg MOG (35-55) peptide.  
Seventeen days later during the peak of the induction phase, mice in the treated 
group were gavage- fed 1.0 mg/kg of the inhibitor daily for fourteen consecutive 
days.  Vehicle controls were given 15 percent DMSO in 0.5 percent 
methylcellulose daily for the same fourteen days as the inhibitor was given. The 
mice were fasted prior to inhibitor administration.  Mice fed CPSI-00155F 
exhibited less severe EAE during inhibitor treatment , but the protection was less 
dramatic than with the i.p. administration route (Figure 3.1).  Still, mice in the 
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CPSI-00155F oral inhibitor treated group followed the trend of a lower 
cumulative disease index  relative to both the CPSI-00155S orally treated mice 
and vehicle controls (22.38 compared to 30.25 and 25.31, respectively; Table 3.2).  
Additionally, the mice in the CPSI-00155F inhibitor treated group had a reduced 
mean score relative to the CPSI-00155S treated mice (1.60 compared to 2.16; 
p<0.05, Table 3.2). 
A second small molecule inhibitor of MIF from Cytokine Pharmasciences was 
tested for its effectiveness when administered orally.  CPSI-00156F was found to 
be as effective as CPSI-00155F when administered via i.p. injection.  We sought 
to determine if CPSI-00156S is effective at treating ongoing EAE when given 
orally (Figure 3.3).  Wild-type C57Bl/6 mice were immunized for EAE with 200 
μg MOG (35-55) peptide.  Seventeen days later during the peak of the induction 
phase, mice in the treatment groups were fed either 0.1, 1.0, or 10.0 mg/kg of 
CPSI-00156S daily for fourteen consecutive days.  Vehicle controls were given 15 
percent DMSO in 0.5 percent methylcellulose daily for the same fourteen days as 
inhibitor administration.  We observed the inhibitor to be effective at the lowest 
administered dose of 0.1 mg/kg, with its most effective dose at 1.0 mg/kg dose.  
Mice in the 1.0 mg/kg CPSI-00156S inhibitor treated group had a reduced CDI 
relative to the vehicle controls (10.00 compared to 15.60, p<0.05, Table 3.3).  
Additionally, the mice in the 1.0 mg/kg CPSI-00156S inhibitor treated group had 
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a lower mean score relative to vehicle controls (0.71 compared to 1.14, p<0.05, 
Table 3.3).  
We concluded that a small molecular inhibitor of MIF was effective at reducing 
ongoing EAE when administered orally. This finding was corroborated with two 
additional inhibitors from Cytokine Pharmasciences, CPSI-1306 and CPSI-2705 
(data not shown).  These inhibitors proved effective at an oral dose of 1.0 mg/kg.       
3.3 Discussion 
Previous studies in mouse models with the genetic deletion of MIF showed the 
importance of MIF in the progression of EAE.  Taken together with the 
observation of increased MIF levels in the cerebrospinal fluid of MS patients 
during relapses, this data argues for the importance of MIF in MS pathology as 
well  (Gao, 2008).  We sought to explore the role of MIF in EAE and MS by 
utilizing several small molecule inhibitors of MIF through collaboration with 
Cytokine Pharmasciences.  We found that small molecule inhibitors of MIF are 
effective at reducing the progression of EAE.     
We investigated the oral effectiveness of the inhibitors.  With the exception of 
Fingolimod, the promising oral therapy in phase III clinical trials, oral therapies 
for MS are nonexistent.  The success of the inhibitors at reducing EAE clinical 
signs in ongoing EAE when administered orally is very promising and novel.  A 
limitation to the oral studies involved the necessary fasting of the mice.  Mice 
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from both the treated and vehicle groups were fasted before the treatment was 
administered.  During the inhibitor studies, we observed a slight recovery in the 
vehicle treated groups in place of the predicted worsening of disease.  Recent data 
shows reduced caloric intake through fasting may be protective in MS patients 
(Piccio L., 2008).  Fasting presents a stress on the body, calling for increased 
production of stress steroids which may suppress the immune system thereby 
serving as protective in the autoimmune attack of MS.    
The oral effectiveness of the inhibitors was investigated at three different doses: 
0.1 mg/kg, 1.0 mg/kg, and 10 mg/kg.  The treatment trended to lower clinical 
signs at all doses, but the effective dose was found to be the 1.0 mg/kg oral dose.  
The low-dose efficacy presents a large advantage for therapy, reducing toxicity 
and side effects.  Additionally, testing performed by Cytokine Pharmasciences 
showed the MIF inhibitors to be safe for patient administration.   
Given MIF’s ubiquitous expression, determining the biologically relevant source 
of MIF would provide a more specific and safer therapeutic target.  MIF has been 
shown to be important in the innate immune response, thus total depletion of 
MIF may have adverse side effects on patients (Terrazas C.A., 2010).  
Identification of a specific cell type which produces the biologically relevant MIF 
in EAE would allow for a specific therapeutic target, perhaps through the use of 
a small-interfering RNA.  Additionally, because MIF is a pro-inflammatory 
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cytokine, identifying the relevant source of MIF would help elucidate the 
mechanism of how MIF mediates the inflammatory response seen in MS.    
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Figure 3.1: A small molecule inhibitor of MIF reduces disease 
severity in EAE.
A: Male wild-type mice were injected with MOG (35-55) peptide and monitored 
daily for clinical signs.  At 17 days post immunization, mice in the inhibitor 
treated group were injected daily i.p. with 10.0 mg/kg CSPI-00155S (    ,  n=10) 
or CPSI-00155F (    , n=10).   Vehicle controls (    , n=8) were given 25 percent 
DMSO in 0.5 percent methylcellulose.   Treatment was given for 14 days.   Mice 
given the inhibitor CPSI-00155F had reduced severity when compared to the 
inhibitor CPSI-00155S and the vehicle controls.   Data are representative of two 
separate experiments. 
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TREATMENT n CDIa MEAN SCOREb
Vehicle 8 11.82 0.65
CPSI-00155S 10 10.36 0.78
CPSI-00155F 10 7.50* 0.47
Table 3.1: A small molecule inhibitor of MIF reduces disease severity 
in EAE.
Wild-type mice were immunized for EAE with 200 μg MOG (35-55) and given 
inhibitor seventeen days later for fourteen consecutive days.
a Cumulative disease index (CDI) was calculated as the sum of clinical scores 
during inhibitor administration per animal and averaged within each group.
b Mean score was measured over the duration of treatment per animal and 
averaged within each group.
* p<0.05 compared to the vehicle by Student’s t- Test
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Figure 3.2: CSPI-00155F is not as effective when administered 
orally.
Male wild-type mice were injected with MOG (35-55) peptide and monitored 
daily for clinical signs.  At 17 days post immunization, mice in the inhibitor 
treated group were fed daily 1.0 mg/kg CSPI-00155S (    , n=8) or CPSI-
00155F (    , n=8).   Vehicle controls (    , n=8) were given 15 percent DMSO in 
0.5 percent methylcellulose.  Treatment was given for 14 days and mice were 
fasted approximately eight hours before inhibitor administration.  Mice given 
the inhibitor CPSI-00155F had reduced severity of ongoing EAE but the 
protection was not as dramatic as seen with the i.p. administration route.  
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TREATMENT n CDIa MEAN SCOREb
Vehicle 8 25.31 1.81
CPSI-00155S 8 30.25 2.16
CPSI-00155F 8 22.38* 1.60*
Table 3.2: CSPI-00155F is not as effective when administered orally.
Wild-type mice were immunized for EAE with 200 μg MOG (35-55) and fed 
inhibitor by gavage seventeen days later for fourteen consecutive days.
a Cumulative disease index (CDI) was calculated as the sum of clinical scores 
during inhibitor administration per animal and averaged within each group.
c Mean score was measured over the duration of treatment per animal and 
averaged within each group.
*p<0.05 compared to CPSI-00155S by Student’s t Test.
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Figure 3.3: Oral inhibitor doses of CPSI-00156S are effective at 
doses as low as 0.1 mg/kg.
A: Male C57Bl/6 wild-type mice were injected with MOG (35-55) peptide 
and monitored daily for clinical signs.  At 17 days post immunization, mice 
in the inhibitor treated groups were fed daily 10, 1.0, or 0.1 mg/kg CSPI-
00156S (n=8 for each group).  Vehicle controls (n=5) were fed 15 percent 
DMSO in 0.5 percent methylcellulose.  Mice were treated for 14 days and 
mice were fasted approximately eight hours before inhibitor administration.  
Mice treated with the inhibitor showed less severe EAE.  The 1.o mg/kg (     ) 
group showed significantly reduced scores compared to the vehicle treated 
group (p<0.05).
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Table 3.3: Oral inhibitor doses of CPSI-00156S are effective at doses as 
low as 0.1 mg/kg.
Wild-type mice were immunized for EAE with 200 μg MOG (35-55) and gavage
fed inhibitor seventeen days later for fourteen consecutive days.
a Cumulative disease index (CDI) was calculated as the sum of clinical scores 
during inhibitor administration per animal and averaged within each group.
c Mean score was measured over the duration of treatment per animal and 
averaged within each group.
*p<0.05 compared to the vehicle group by Student’s t Test.
TREATMENT n CDIa MEAN SCOREb
Vehicle 5 15.60 1.14
0.1 mg/kg 8 14.25 1.01
1.0 mg/kg 8 10.00* 0.71*
10.0 mg/kg 8 13.69 0.93
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C h a p t e r  4  
THE RELEVANT MIF IN EAE IS BONE MARROW DERIVED 
MIF is constitutively produced and stored throughout the body in a wide variety 
of immune cells, including monocytes, macrophages, dendritic cells, B 
lymphocytes, T lymphocytes, neutrophils, mast cells and basophils.  Additionally, 
MIF is found in endothelial cells and epithelial cells lining the lung, 
gastrointestinal and urogenital tracts (Denkinger, 2003).  MIF has been described 
as a mediator of inflammation and because EAE is mediated by pro-
inflammatory cytokines, we hypothesized that the relevant MIF in EAE was 
likely to be produced by a specific immune cell.    In addition to the pro-
inflammatory properties, we hypothesized a specific source of MIF because of its 
local mechanism of action taken with the specific environment of the CNS. 
Identification of the specific cell type would shed light on the inflammatory 
pathway in EAE and would allow for a better therapeutic target for multiple 
sclerosis treatment. 
In this chapter, we investigate a possible source of the relevant MIF.  We first 
explore immune cells, since the pro-inflammatory properties of MIF and its 
involvement in EAE progression suggest an immune linkage.  Next we turned 
our investigation to determining the specific immune cell producing MIF in 
EAE, starting with the likely source of T lymphocytes.   
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4.1 The Biologically Relevant MIF is Bone Marrow Derived. 
To test our initial hypothesis that the relevant MIF in EAE is from an immune 
source, we created bone marrow chimera mice.  The immune system is derived 
from the bone marrow.  Our bone marrow chimera models allowed us to 
investigate the immune compartment separate from the nervous system, which is 
also involved in MS pathology.  We started with a MIF-/-x RAG-/- double 
knockout mouse (Figure 4.1A).  RAG-/- mice are deficient in the recombination 
activating gene (RAG) which is necessary for proper B and T lymphocyte 
development.  Thus, RAG-/- mice are deficient in B and T lymphocytes and   
MIF-/- x RAG-/- mice are deficient in MIF in addition to B and T lymphocytes.  
We irradiated the MIF-/-x RAG-/- mice in order to ablate their immune systems.  
Immediately following the irradiation, we reconstituted the MIF-/-x RAG-/- mice 
with bone marrow from a wild-type donor (WTKO).  After six weeks, allowing 
for reconstitution of the immune system, the MIF-/- mouse has the immune 
system of a wild-type mouse.  The mouse remains deficient in MIF in the 
nervous system but now has MIF present in the immune compartment.  The 
converse situation was also created by reconstituting a RAG-/- mouse with MIF-/- 
bone marrow (KOWT).  Controls were also included, by reconstituting a    
MIF-/-x RAG-/- mouse with MIF-/-bone marrow (KOKO) and reconstituting a 
RAG-/- mouse with wild-type bone marrow (WTWT).   
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After the chimeric mice were created, we immunized each group with MOG (35-
55) to determine susceptibility to EAE (Figure 4.1B and C).  The chimeric mice 
expressing MIF in their immune compartment (WTKO and WTWT) 
exhibited increased susceptibility regardless of MIF production in the nervous 
system.  However, when MIF was absent from the immune system (KOWT 
and KOKO), the mice showed less severe clinical signs.   
These results are shown in Table 4.1.  The phenotype of the central nervous 
system is the same as the recipient mouse whereas the source of the antigen 
presenting cells and T lymphocytes is the same as the donor bone marrow.   The 
shaded boxes highlight the involvement of MIF from bone marrow derived 
immune cells in EAE, showing disease is more severe when MIF is present in the 
bone marrow.   
4.2 T Lymphocytes Alone Expressing MIF are not Sufficient for EAE 
Pathogenesis.   
Determining that relevant MIF is bone marrow derived narrowed our focus to 
cells of the immune system.  The immune system is divided into two important 
lineages: myeloid and lymphoid (Figure 4.2).  The myeloid lineage gives rise to the 
antigen presenting cells, most noticeably dendritic cells and monocytes.  On the 
other hand, the lymphoid lineage gives rise to B and T lymphocytes.  We 
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continued our investigation with T lymphocytes because they were one of the 
early cell types linked to MIF production (David, 1967).   
 
In order to determine whether T lymphocytes are the possible source of MIF, we 
utilized an adoptive transfer model (Figure 4.3A).  We immunized a wild-type 
mouse with MOG (35-55) peptide and after fourteen days, isolated the T 
lymphocytes.  Next, we re-activated the T lymphocytes in vitro with MOG (35-55) 
peptide.  The re-stimulated T lymphocytes from the wild-type donor mouse were 
next adoptively transferred to a naïve MIF-/- mouse, resulting in a mouse that 
only produced and expressed MIF in T lymphocytes (WTKO).  The converse 
situation was created by adoptively transferring re-activated T lymphocytes from 
a MIF-/- mouse into a naïve wild-type mouse (KOWT).  Appropriate control 
mice were also included by adoptively transferring re-activated T lymphocytes 
from a wild-type mouse into a naïve wild-type mouse (WTWT) and 
transferring re-activated T lymphocytes from a MIF-/- mouse into a naïve MIF-/- 
mouse (KOKO).  Mice in each group were monitored daily for clinical scores. 
 
We observed significantly reduced clinical scores in the mice only expressing MIF 
in the T lymphocytes (WTKO) when compared to the wild-type control group 
(WTWT) (Figure 4.3B).  We also observed increased susceptibility of wild-type 
mice receiving re-activated MIF-/-  T lymphocytes (KOWT) when compared to 
the knockout control group (KOKO) (Figure 4.3C).  These results are shown 
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in Table 4.2.  In the above adoptive transfer experiments, we controlled the 
expression of MIF from T lymphocytes while allowing MIF expression to remain 
consistent between the central nervous system and the antigen presenting cells 
(APCs).   The observed protection of the MIF knockout environment (CNS and 
APCs) regardless of MIF production by the T lymphocytes led us to conclude T 
lymphocytes are not the relevant source of MIF. 
 
4.3 Discussion 
We have previously shown MIF plays a role in the progression of EAE.  
Hypothesizing the relevant MIF has a specific cellular source, we investigated 
whether this source was derived from the immune system or the nervous system.  
We utilized a chimera system to investigate MIF from the nervous system and 
immune system.  Our results showed that MIF from the bone marrow was 
critical for EAE progression.  With this result, our focus narrowed to the myeloid 
and lymphoid compartments within the bone marrow.  Given the strong 
connections between MIF production and T lymphocytes taken with the 
undisputed connections between T lymphocytes and EAE, we first investigated 
the impact of MIF production by T lymphocytes.  Adoptive transfer experiments 
showed that MIF production by T lymphocytes was unnecessary for EAE 
susceptibility.  Taken together, these results allow us to conclude that the relevant 
source of MIF is bone marrow derived, yet not from T lymphocytes.   
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In the ensuing chapters, we will continue to investigate the lymphoid lineage to 
determine the relevant source of MIF.  The second important lymphocyte in 
EAE pathology is the B lymphocyte, which will be explored next. 
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Figure 4.1: The expression of MIF by bone marrow derived cells 
is required for the progression of EAE. 
A: Wild-type and MIF-deficient RAG knockout mice were irradiated and 
reconstituted with wild type or MIF-deficient bone marrow.  Six weeks later 
(to allow for adequate reconstitution), mice were immunized with MOG(35-
55) peptide and monitored daily for clinical signs.
B: MIF produced from bone marrow derived cells was sufficient to induce 
EAE but MIF knockout  bone marrow in wild-type recipients greatly reduced 
susceptibility to EAE.
C:  Wild-type bone marrow increased susceptibility to EAE in knockout 
recipient mice.
Data are representative of two separate experiments (n=5 per group per 
experiment) 
*This work was done in collaboration with Aaron P. Kithcart, PhD.
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CNS APCs T cell EAE
WTKO NO MIF MIF MIF YES
WTWT MIF MIF MIF YES
KOKO NO MIF NO MIF NO MIF NO
KOWT MIF NO MIF NO MIF NO
Table 4.1: The expression of MIF from bone-marrow derived cells 
was sufficient for the induction of EAE.
Bone marrow chimeric mice expressing MIF in bone marrow derived cells 
are susceptible to EAE.
CNS: central nervous system
APCs: antigen presenting cells
*This work was done in collaboration with Aaron P. Kithcart, PhD.
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BONE MARROW
LYMPHOID
(Lymphocytes)
MYELOID
(APCs)
T CELL B CELL MONOCYTE DENDRITIC
CELL
Figure 4.2: Bone Marrow Derived Lineages and Cell Types
Bone marrow derived cells serve as the source for the lymphoid and myeloid 
compartments.  The lymphoid lineage gives rise to lymphocytes, namely B 
and T lymphocytes.  The myeloid line gives rise to antigen presenting cells, 
such as monocytes and dendritic cells.
APCs: antigen presenting cells
 39 
 
 
-/- -/-
Day 0: 
Active immunization 
of WT mice
Day 14-17: 
In vitro reactivation of 
WT T lymphocytes
+
Day 21:  
Adoptive transfer 
to MIF-/- mice
?
Monitor for clinical 
signs
A:
B:
Figure 4.3: T lymphocytes alone expressing MIF are not sufficient 
to induce EAE
A: Following 72 hours in vitro reactivation, 10x106 T lymphocytes from 
wild-type or MIF deficient mice were adoptively transferred into naïve 
recipient wild-type or MIF knockout mice.
B: Wild-type T lymphocytes were unable to induce EAE in MIF-deficient 
recipients.
C: MIF deficient T lymphocytes could induce EAE in wild-type recipient 
mice.
Data are representative of four separate experiments (n=5 per group per 
experiment)
C:
*This work was done in collaboration with Aaron P. Kithcart, PhD.
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CNS APCs T cell EAE
WTWT MIF MIF MIF YES
KOWT MIF MIF NO MIF YES
WTKO NO MIF NO MIF MIF NO
KOKO NO MIF NO MIF NO MIF NO
Table 4.2: MIF is required in recipient mice for EAE induction via 
adoptive transfer with T lymphocytes.
Expression of MIF from CNS and antigen presenting cells was required for 
adoptive transfer of EAE by activated leukocytes.  
CNS: central nervous system
APCs: antigen presenting cells
*This work was done in collaboration with Aaron P. Kithcart, PhD.
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C h a p t e r  5  
MIF DEFICIENT MICE HAVE A MODIFIED B LYMPHOCYTE 
POPULATION 
After determining that the relevant cellular source of MIF is bone marrow 
derived and eliminating T lymphocytes as the cell of origin, we continued our 
investigation of the lymphoid lineage of the immune system.  The role of B 
lymphocytes in EAE and MS is unclear but has recently emerged as an area of 
interest with the recent success of Rituximab (Hauser S., 2008).  Rituximab is a 
monoclonal antibody against CD20, which is a specific human B lymphocyte 
marker. Thus, the significant improvement of MS patients taking Rituximab 
argues for a role of B lymphocytes in MS pathology. 
 
Additionally, recent findings suggest that MIF may be important for B 
lymphocyte maturation and development (Gore Y., 2008).  MIF has been shown 
to be important for the maintenance of the mature B lymphocyte population 
active during the adaptive immune response, which is the primary form of 
response in the autoimmune attack of MS.  In this chapter, we will first explore B 
lymphocyte maturation in an MIF knockout mouse compared to a wild-type 
mouse.  Thereafter, we will explore the proliferative properties of B lymphocytes 
in an MIF deficient environment compared to a wild-type environment.  Because 
it has been suggested that MIF provides survival signals to B lymphocytes, we 
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hypothesize that mature B lymphocytes will be fewer in number and less effective 
at proliferating.     
 
5.1    MIF Deficient Mice Have Fewer Mature B Lymphocytes 
We compared the B lymphocyte population in MIF knockout relative to wild-
type mice.  We analyzed three stages in B lymphocyte development (pro-B, 
immature B and mature B lymphocytes) in addition to a pan B lymphocyte 
marker.  Figure 5.1 shows the three major stages of a B lymphocyte which we 
characterized.  Total B lymphocyte percentages are represented as the percentage 
of the total live cell population that are B220 positive, which is considered a pan 
B lymphocyte marker.  Pro-B lymphocytes were identified as B220 positive cells 
which were negative for IgM and IgD.  Immature B lymphocytes were identified 
as B220 positive cells which were IgM positive and IgD negative.  Mature B 
lymphocytes were identified as B220 positive cells which were positive for both 
IgM and IgD.   
 
We compared the B lymphocyte population of naïve MIF knockout mice and 
naïve wild-type mice in three immune organs: the lymph nodes, the bone 
marrow, and the spleen.  No significant differences were found in lymph nodes 
between an MIF deficient and a naïve wild-type mouse (Figure 5.2A).   
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The bone marrow showed significantly fewer B lymphocytes in the naïve MIF 
knockout mouse (Figure 5.2B).  A larger percent of the total cell population 
(30.2%) was B220 positive (indicating B lymphocytes) in the wild-type mouse 
compared to 18.8 percent in the MIF knockout mouse (p<0.05).   
 
The trend observed in the bone marrow of fewer overall B lymphocytes, more 
pro-B lymphocytes, and fewer mature B lymphocytes in the MIF deficient 
environment was much more dramatic in the spleen (Figure 5.2C).   The B 
lymphocyte percentage in the MIF knockout mice was less than half that of the 
wild-type control (26.3 percent verse 55.8 percent, respectively; p<0.05).  Even 
more striking was the difference in the B lymphocyte subtypes.  94.6 percent of 
the B lymphocyte population was positive for the pro-B lymphocyte markers in 
the MIF knockout compared to only 2.6 percent in the wild-type control 
(p<0.001).  Interestingly, the mature B lymphocyte population of the MIF 
knockout mice was significantly reduced when compared to the wild-type 
controls (1.83% versus 91.0%, respectively; p<0.001).  
 
 These results support our hypothesis that MIF is involved in the survival of B 
lymphocytes.  The MIF deficient mice had fewer mature B lymphocytes and 
more pro-B lymphocytes leading us to conclude MIF is involved in B lymphocyte 
survival.   
 
 44 
 
5.2 B Lymphocytes Proliferate Less in the Bone Marrow of MIF Deficient 
Mice 
After determining that MIF deficient mice have fewer mature B lymphocytes, we 
investigated the in vivo proliferative ability of B lymphocytes in a MIF deficient 
and wild-type environment.  To explore this, we used CFSE (a fluorescent dye), 
which is incorporated into B lymphocytes and which fluoresces less with each 
successive cell division.  This model is depicted in Figure 5.2A.  First, we isolated 
B lymphocytes from wild-type donors (>90% purity).  Next, we labeled the 
purified B lymphocytes with the CFSE dye and transferred them intravenously 
into either MIF-/-x RAG-/- double knockout or RAG-/- knockout recipient mouse.  
In addition to the stained B lymphocytes, non-labeled wild-type T lymphocytes 
were transferred into the recipient mice to allow for proper EAE induction.  
Immediately following the cell transfer, the recipient mice were immunized with 
MOG (35-55).  Seven days post immunization, the recipient mice were sacrificed 
and proliferation of the CFSE positive B lymphocytes was analyzed in the three 
immune organs (the lymph nodes, bone marrow, and spleen).  Control mice were 
included which were not immunized.      
 
B lymphocyte proliferation in the non-immunized control mice (black line in 
Figure 5.3B, C, and D) shows slightly less CFSE peaks corresponding to less 
proliferation.  When comparing the proliferative ability of B lymphocytes in a 
MIF deficient environment (green line, Figure 5.3B, C, and D) compared to a 
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wild-type environment (orange line, Figure 5.3B, C, and D), a noticeable 
difference is apparent in the bone marrow (Figure 5.3D).  The B lymphocytes 
proliferate less in the bone marrow of a MIF deficient mouse.  This result 
corresponds with our previous finding that the source of relevant MIF is bone 
marrow derived.  Thus, in a MIF deficient mouse, B lymphocyte proliferation is 
impaired in the bone marrow, perhaps offering the protection observed of the 
MIF deficient mice when immunized for EAE. 
 
5.3 Discussion 
The role of B lymphocytes in MS is currently poorly understood, yet there are 
many diverse hypotheses to explain the role of B lymphocytes in EAE and MS 
(M.K., 2008).  The vast majority of these hypotheses implicate B lymphocytes in 
the autoimmune response through antigen presentation, auto-antibody 
production, or cytokine production.  B lymphocytes in EAE could aid the 
inflammation process through recruitment of the immune cells via cytokine 
production and antibody tagging.  MIF may be the key cytokine mediator of B 
lymphocytes, which causes the severe inflammation of EAE and mediates the 
damage to the CNS. 
 
We have shown that the mature B lymphocyte population is modified in a MIF 
deficient environment.  Fewer mature B lymphocytes are present in a MIF 
deficient mouse and the proliferative ability of these B lymphocytes is impaired.  
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The results argue that without MIF present in the bone marrow, B lymphocytes 
are unable to proliferate sufficiently.  This would result in fewer mature B 
lymphocytes, which may be the source of protection.   
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Figure 5.1: B lymphocyte maturation markers
The above cell markers were used to identify  the B lymphocyte cell subtypes at the different 
stages of development.  Pro-B lymphocytes were identified as IgM-/IgD- gated on the 
B220+ cell population.  Immature B lymphocytes were identified as IgM+/IgD- gated on 
the B220+ cell population. Lastly,  mature B lymphocytes were identified as IgM+/IgD+ 
gated on the B220+ cell population.
B220
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IL-7R
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Figure 5.2: MIF deficient mice have fewer mature B lymphocytes than wild-
type counterparts
A,C, and D: Lymph nodes (A), bone marrow (C), and spleens (D) were removed from 
naïve MIF deficient mice and wild-type mice.  B cell percentages are gated on total  cell 
population.  Pro-, immature, and mature B cell numbers are gated on total B cell 
population.   n=3 for each group.
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Figure 5.3:  B cells proliferate less in the bone marrow of MIF knockout 
mice
Purified B cells (>90% purity) were CFSE labeled and transferred into MIF-/- x    
RAG-/- or RAG-/- recipients (A).  The recipients were immunized with 200 ug
MOG(35-55) in adjuvant.  Seven days post immunization, spleens (B), lymph nodes 
(C), and bone marrow (D) were isolated and evaluated for CFSE fluorescence.   Non-
immunized mice were used as a negative control (black line).  Fewer peaks 
corresponding to less proliferation is seen in the bone marrow of MIF knockout 
mice.  Data are representative of two separate experiments, n=4 for each group.
A:
B: Spleen C: Lymph Node D: Bone Marrow
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C h a p t e r  6  
IN VIVO MIF PROUCTION BY B LYMPHOCYTES  
We have shown that the B lymphocyte population is different in the MIF 
deficient environment.  We next evaluated the in vivo contribution of MIF 
production by B lymphocytes during ongoing EAE.  We hypothesized that B 
lymphocytes are the cell source through which MIF mediates the crucial  pro-
inflammatory effects during ongoing EAE.  Recent studies show MIF signals 
through the Akt pathway (Lue H., 2007).  This pathway is autocrine in nature, 
suggesting B lymphocytes may be responsive to the MIF they themselves 
produce.  In this manner, B lymphocytes could represent an ideal mediator of 
inflammation and therapeutic target for MS.  After trafficking to the site of 
inflammation in the CNS, it is plausible that B lymphocytes could be activated by 
the local cytokine milieu to produce MIF which could then act back on the B 
lymphocytes in an autocrine fashion for further activation or antibody production 
(Figure 6.1).  We have previously eliminated the T lymphocytes as the relevant 
cellular source of MIF and are currently proposing an autocrine mechanism for 
MIF produced by B lymphocytes. 
 
6.1 EAE Can Be Induced in a RAG-/- Mouse 
In order to further investigate the in vivo MIF production by B lymphocytes, we 
utilized the RAG-/- mouse.  To test our question regarding the autocrine nature of 
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MIF, we felt it important to immunize RAG-/- mice rather than transferring 
disease through an adoptive transfer model.  Since RAG-/- mice are deficient in 
both B and T lymphocytes, the immunization process with MOG (35-55) had to 
be investigated.   
 
T lymphocytes are crucial for EAE induction  (Noseworthy J. W., 2000), thus we 
began our studies with the transfer of purified T lymphocytes (>95% purity) into 
the RAG-/- mouse before immunization with MOG (35-55) (Figure 6.2A).  We 
studied the i.p. injection of T lymphocytes immediately before (data not shown) 
or two days prior to immunization (Figure 6.2B).  Injection of the T lymphocytes 
into the intraperitoneal cavity immediately followed by immunization was not 
successful in inducing EAE.  We suspect this is because the T lymphocytes were 
not given adequate time to traffic to the proper locations in order to be in 
position to mount the necessary immune response for EAE.  However, the i.p. 
injection of the T lymphocytes two days prior to immunization was sufficient for 
EAE induction (Figure 6.2B).  Injection of 5x106 T lymphocytes resulted in the 
highest cumulative disease index and peak score (37.5 and 3.83, respectively; 
Table 6.1).  Controls included immunizing RAG-/- mice without transferring T 
lymphocytes.   Additionally, we included RAG-/- mice receiving the T lymphocyte 
transfer but not immunized with MOG (35-55).  EAE failed to develop in either 
of these two control groups.  However, the day of onset for all experimental 
groups was much later than expected for EAE (Gold, 2000).  Although we could 
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successfully induce EAE in a RAG-/- mouse, we desired a more robust disease 
course and next investigated the intravenous injection route.   
  
We intravenously transferred T lymphocytes into RAG-/- recipients and 
immediately immunized for EAE on the same day as the transfer (Figure 6.2C).  
With this protocol, the day of onset of clinical signs was observed at a much 
earlier time point (17.5 versus 40 days post immunization; Table 6.1).  The 
intravenous transfer of 1x106 purified T lymphocytes resulted in the most 
pronounced EAE course with a cumulative disease index of 73.8 and a peak 
score of 3.25 (Table 6.1).   
 
To confirm the presence of T lymphocytes in the CNS, we performed staining of 
the CD4+ T lymphocytes in the brain and spinal cord tissue (Figure 6.3).  1x106 
purified T lymphocytes were transferred i.v. into a RAG-/- mice.  Immunization 
with MOG (35-55) immediately followed the transfer.  The infiltration of T 
lymphocytes in the usually immune privileged CNS tissue is a hallmark of EAE 
and MS pathology.  Thus, the observed clinical scores are supported by the 
infiltration of T lymphocytes in the CNS. 
After comparing both methods of EAE induction, via i.p. or i.v. injections, it 
became apparent that the i.v. injection of 1x106 purified T lymphocytes was the 
most pathogenic and feasible with respect to the number of necessary donor cells 
needed.  Since this method resulted in the reliable induction of EAE, we will use 
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this protocol in the following sections to investigate the autocrine MIF 
production by B lymphocytes. 
 
6.2 The Most Pathogenic Ratio is 2:1 T:B Lymphocytes 
After determining a method to induce EAE in a RAG-/- mouse, it was necessary 
to incorporate B lymphocytes into our protocol.  In order to do this, we first 
determined the ideal ratio of T and B lymphocytes to induce high activation and 
proliferation of the lymphocytes.  We purified T (>95% purity) and B (>90% 
purity) lymphocytes and co-cultured them in varying ratios (Figure 6.4).  The co-
cultures were treated with anti-CD3, a stimulus to mimic the in vivo activated 
environment during EAE.  Controls included un-stimulated cells, which lacked 
anti-CD3 stimulation (data not shown).  The cell cultures were analyzed for 
activation markers (Figure 6.4) and proliferation (Figure 6.5).  The activation 
markers evaluated by flow cytometry were CD25 (Figure 6.4B) for T lymphocytes 
and CD80 (Figure 6.4C) for B lymphocytes.  Both ratios of 1:1 and 2:1 T:B 
lymphocytes yielded a high percentage of activation markers (Figure 6.4).   
 
In addition to the activation markers, we evaluated the cultures for proliferation. 
The T lymphocytes were stained with the fluorescent dye CFSE, which decreases 
in intensity with each successive cell division.  At 48 hours, the 2:1 T:B 
lymphocyte data expressed the greatest shift corresponding to the greatest extent 
of proliferation (Figure 6.5).  This data, taken with the above activation marker 
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data, shows that the most potentially pathogenic ratio for our EAE studies is the 
2:1 T:B lymphocyte ratio.  Interestingly, this is the approximate observed ratio of 
lymphocytes in the human spleen  (Peterson L.K., 2008).   
 
6.3    MIF Present in B Lymphocytes Alone is not Sufficient to Induce 
EAE. 
After establishing a method to reliably induce EAE in a RAG-/- mouse and 
determining the optimum lymphocyte ratio, we narrowed our focus to the in vivo 
autocrine MIF production by B lymphocytes.  To create a mouse model where 
the only source of MIF is B lymphocyte derived, we first purified T lymphocytes 
from an MIF-/- donor mouse and B lymphocytes from a wild-type donor mouse 
(Figure 6.6A).  The purified cells were next transferred via i.v. injections into an 
MIF-/- x RAG-/- recipient mouse and this mouse was immunized for EAE with 
MOG (35-55).  The only source of MIF in this mouse model was from the B 
lymphocytes.  Control groups were also immunized (Figure 6.6).  
 
We found that the ability of B lymphocytes to produce MIF was not sufficient 
for EAE induction.  Mice with MIF present in the recipient mouse experienced 
more severe EAE regardless of the ability of B lymphocytes to produce MIF 
(Figure 6.6B).  This allowed us to conclude that MIF production by B 
lymphocytes is not the relevant source of MIF in EAE.     
 
 55 
 
6.4 MIF Production by B and T Lymphocytes Together is not Sufficient 
for EAE Progression 
To confirm that MIF produced by T lymphocytes does not act on B lymphocytes 
thereby representing the relevant source of MIF in EAE, we developed a second 
mouse model in which the ability to produce MIF was kept constant between the 
donor B and T lymphocytes (Figure 6.7A).  With this model, the MIF produced 
by the T lymphocytes could be the necessary MIF for the B lymphocytes or vice 
versa.  However, these results too showed that the MIF knockout recipients 
exhibited a milder course of EAE (Figure 4B). Thus, we can conclude that 
relevant source of MIF in EAE is not lymphocyte derived. 
 
6.5 Discussion 
MIF has been shown to activate the Akt pathway which has an autocrine 
mechanism.  We show that MIF production by B lymphocytes alone is not 
sufficient to restore EAE susceptibility in an MIF deficient mouse.  We have also 
shown previously that T lymphocytes are not the relevant source of MIF by 
themselves or in combination with B lymphocytes.  
 
One potential caveat to this study is that B lymphocytes are not critical to the 
induction of EAE with the MOG (35-55) peptide and therefore the role of MIF 
production by B lymphocytes may be masked in our model.  However if this 
were the case, we would not expect to observe the protection seen in the MIF 
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deficient mice.  When naïve MIF deficient mice are immunized with MOG (35-
55) peptide, susceptibility to EAE is greatly reduced.  Thus, if our model were 
masking the MIF contribution of B lymphocytes, we would expect to observe 
this masking in the MIF deficient mouse as well.  We do not think immunizing 
with MOG (35-55) is masking the role of B lymphocytes with respect to MIF 
production.    
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Figure 6.1: Possible Roles of B Lymphocytes after  MIF activation
Though we have previously shown that MIF produced by T lymphocytes is not sufficient 
to induce EAE, we propose MIF acts in an autocrine manner to affect B lymphocytes.  
Possible results of B lymphocyte activation by MIF is enhanced antigen presentation 
enhanced trafficking into the central nervous system (CNS), or enhanced T lymphocyte 
activation.    
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Figure 6.2: EAE can be induced in a RAG-/- mouse.
A: EAE induction in a RAG knock out.  T lymphocytes (>95% purity) were transferred 
either i.p. (B) or i.v. (C) into RAG-/- mice 2 days prior to or immediately before active 
immunization with MOG (35-55) peptide.  
B: CD4+ T lymphocytes (>95% purity) were transferred i.p.  into RAG-/- mice 2 days 
prior to active immunization with MOG (35-55) peptide.  The day of onset was late 
compared to a wild-type active immunization (data not shown).  n=4 for each group.
C: CD4+ T lymphocytes (>95% purity) were transferred i.v. into RAG-/- mice 
immediately prior to active immunization with MOG (35-55) peptide.  1.0x106
transferred CD4+ T lymphocytes exhibited typical day of onset and disease course.  n=3 
for each group.
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# CD4+
wild-type 
cells INCIDENCE ONSETa CDIb
PEAK 
SCOREc
0.5x106 iv 33% 29 ± 13.7 ND ND
1.0x106 ip 0% ND ND ND
1.0x106 iv 67% 17.5 ± 8.50 73.8 ± 12.8 3.25 ± 0.75
2.0x106 ip 50% 35.5 ± 18.50 9.7 ± 6.8 1.75 ± 0.75
2.0x106 iv 67% 20.5 ± 10.33 51.8 ± 39.6 3.75 ± 0.25
5.0x106 ip 75% 40 ± 20.35 37.5 ± 28.2 3.83 ± 0.24
5.0x106 iv 0% ND ND ND
10.0x106 ip 100% 36 ± 7.93 23 ± 18.7 3.0 ± 0.71
Table 6.1: EAE can be induced in a RAG-/- mouse.
1.0x106 CD4+ T lymphocytes (>95% purity) transferred intravenously into RAG-/-
mice immediately prior to active immunization with MOG (35-55) peptide have 
increased incidence, severity of EAE, and earlier day of onset of disease.
a Day of onset was calculated as the mean of the first day of clinical scores among 
mice that developed EAE, ±SD.
b  Cumulative disease index (CDI) was calculated as the sum of clinical scores day 
7-50 per animal and averaged within each group, ±SD
c Peak score was measured over the duration of disease per animal and averaged, 
±SD.
ND= not determined due to low incidence.
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Figure 6.3: Transferred T lymphocytes are appropriately observed in 
the central nervous system
CD4+ staining confirms the presence of T lymphocytes in the CNS.   CNS tissue 
was isolated on day 26 post active immunization and i.v. transfer of  1x106 CD4+ 
T lymphocytes. 
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Figure 6.4: 2:1 T:B cell ratio is most pathogenic ratio for lymphocyte 
activation markers.
Purified B and T lymphocytes were co-cultured for 24, 48, and 72 hours in differing 
ratios and stimulated with media alone (B, D) or anti-CD3 supplemented media (C,E).  
The presence of CD4+CD25+ (activated T lymphocytes) and CD19+CD80+ (activated 
B lymphocytes) cells were evaluated via flow cytometry.  A ratio of 2: 1 T : B cell 
resulted in the overall greatest  pathogenic phenotype as evidenced by the high 
percentage of activated T and B lymphocytes.  n=3 for each group   
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Histograms representing CFSE peaks at 24 (A), 48 (B), and 72 (C) hours from 
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more distinct peaks, and a greater number of peaks corresponding to a greater 
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Figure 6.6: MIF present in B lymphocytes alone can not induce 
EAE in a MIF knockout recipient.  
A: Purified T lymphocytes (>95% purity) and purified B lymphocytes (>90% 
purity) of opposite donors (MIF knockout or wild-type) were in 
intravenously transferred into MIF-/- x RAG-/- or RAG-/- recipients.  
Immediately following transfer, the mice were immunized for EAE.  Clinical 
scores were observed daily for days 10 through 42.
B: Clinical scores of the different groups shown in (C). Regardless of MIF 
production by B lymphocytes, recipients with MIF in the environment were 
more susceptible to EAE.  
a Cumulative disease index (CDI) was calculated as the sum of clinical scores 
during experiment (days 12-54) per animal and averaged within each group.
b Peak score was measured over the duration of the experiment (days 12-54) 
per animal and averaged within each group.
* p<0.05 for groups compared to groups wild-type recipients.
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Figure 6.7: MIF present in both T and B lymphocytes can not 
induce EAE in a MIF knockout recipient.  
A: Purified T lymphocytes (>95% purity) and purified B lymphocytes (>90% 
purity)  of the same donor were in intravenously transferred into MIF-/- x 
RAG-/- or RAG-/- recipients.  Immediately following transfer, the mice were 
immunized for EAE.  Clinical scores were observed daily for days 10 through 
42.
B: Clinical scores of the different groups shown in (C).   Regardless of the 
lymphocyte phenotype, recipients with MIF in the environment were more 
susceptible to EAE.  
a Cumulative disease index (CDI) was calculated as the sum of clinical scores 
during experiment (days 11-42) per animal and averaged within each group.
b Peak score was measured over the duration of the experiment (days 11-42) 
per animal and averaged within each group.
* p<0.05 for groups compared to groups with wild-type recipients.
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C h a p t e r  7  
DISCUSSION AND CONCLUSIONS 
Previous findings in our laboratory have shown that MIF is important for the 
progression of EAE.  MIF deficient mice exhibit less severe clinical signs during 
the induction phase of EAE with little progression thereafter and some mice 
recovering completely.  The protection seen in the MIF deficient mice led us to 
explore the efficacy of MIF inhibitors.  MIF would be a novel therapeutic target 
since a specific cytokine is yet to be identified as a mediator in MS pathology.  
The majority of the current therapies focus on managing the inflammatory 
response and nearly all are immunosuppressive drugs.  Additionally, none of the 
current therapies are approved for oral administration.  Thus, the oral 
administration of a specific MIF inhibitor would represent a significant 
therapeutic advancement.     
 
We investigated the efficacy of several small molecule inhibitors of MIF, as well 
as the dosing requirements and route of administration.  We demonstrated that 
the pro-inflammatory and autoimmune disease-enhancing effects of MIF are 
reversible with a small molecule MIF inhibitor.  Several different MIF inhibitors 
were shown to be effective at treating EAE by reducing the clinical scores relative 
to the vehicle controls and other stereoisomers.  We observed the inhibitor to be 
effective at doses as low as 1.0 mg/kg when administered orally.  Taken together, 
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the inhibitor studies pinpoint MIF as a viable therapeutic target for the treatment 
of MS.  The reversible effects show that the reduction of MIF levels can be 
effective after onset of disease, representing a clinically relevant time point when 
patients would first see a neurologist for their symptoms.   Additionally, the low 
dose greatly adds to the safety of the inhibitors and may also suggest a level of 
specificity with which MIF mediates the progression of disease.  Lastly, we 
observed that the inhibitor was effective when administered orally, representing a 
novel characteristic for an MS therapy.  However, a more specific MIF inhibitor 
targeted to a defined and critical cell type may effectively treat MS and reduce side 
effects from treatment.  Global inhibition of MIF may weaken the immune 
system, causing increased susceptibility to infectious agents.  MIF may have an 
important immune function in other systems as it may be required for immune 
surveillance. 
 
The next goal was to identify the relevant source of MIF in EAE.  The 
ubiquitous expression of MIF taken together with the low dosing requirement led 
us to hypothesize that the source of biologically relevant MIF in EAE is a specific 
immune cell.  Through a series of bone marrow chimera experiments, we showed 
that the source of the relevant MIF is bone marrow derived.  This finding 
allowed us to exclude the nervous system as the contributor, a viable candidate 
due to the intricate interaction of the immune system with the nervous system in 
MS.  Narrowing our focus to the immune compartment, we hypothesized that T 
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lymphocytes represented the most likely candidate to produce the relevant MIF.  
T lymphocytes were one of the first described cell types in MIF production and 
are critical in MS pathology.  Thus, we performed a series of adoptive transfer 
experiments to determine if MIF production by T lymphocytes alone was 
sufficient to induce disease.  We found that it alone was not sufficient.  Activated 
T lymphocytes from a wild-type donor mouse were unable to restore EAE 
susceptibility in a MIF knockout mouse, showing that MIF production by T 
lymphocytes is not critical for EAE pathology.  However, the recipient 
environment of the mouse proved important.  If MIF was absent from the 
recipient, the mouse was less susceptible to EAE.     
 
Following the elimination of T lymphocytes as the relevant source of MIF, we 
explored B lymphocytes, another bone marrow derived cell, as potentially 
relevant in the progression of EAE.  We first evaluated the B lymphocyte 
population in MIF deficient mice, hypothesizing that if MIF is important for B 
lymphocyte function we would observe a difference in the B lymphocyte 
population of an MIF deficient mouse relative to a wild-type mouse.  MIF 
deficient mice have fewer mature B lymphocytes and more immature B 
lymphocytes when compared to wild-type mice.  This difference was most 
pronounced in the spleen, where the final stages of B lymphocyte maturation 
occur.  The difference in B lymphocyte numbers suggests either a critical survival 
or maturation mechanism is absent in an MIF deficient environment.  Since the 
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relevant MIF is bone marrow derived and B lymphocyte maturation occurs in the 
bone marrow, we hypothesize a critical maturation signal is absent during the 
early stages of B lymphocyte development.   
 
Although rapid B lymphocyte proliferation is characteristic of the bone marrow, 
it may be inhibited if the B lymphocytes are not progressing through the 
maturation process.   Thus, the absence of MIF may inhibit B lymphocyte 
maturation, and the increasing population of pro-B lymphocytes may cause a 
reduction in proliferation, allowing the pro-B lymphocytes time to mature.  Yet, 
without MIF present in the environment, these B lymphocytes may not fully 
mature.  With the reduced proliferation, fewer B lymphocytes enter the secondary 
lymphoid organs, including the spleen.  Fewer mature B lymphocytes taken 
together with fewer overall B lymphocytes in the spleen suggests that not only are 
the pro-B lymphocytes not properly developing, they are also not surviving.  This 
suggests that MIF also plays a role in the survival of B lymphocytes.  The same 
reduction B lymphocyte proliferation may not be observed in the spleen, because 
the few mature B lymphocytes that are available may proliferate adequately in 
response to antigen.  Thus, the difference in the spleen is not the ability to 
proliferate, but that significantly fewer B lymphocytes are available to respond to 
antigen presentation.  The impaired proliferation of B lymphocytes in the bone 
marrow of MIF deficient mice shows that there may be fewer B lymphocytes 
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initially, accentuating the impact of the reduced survival rate observed in the 
spleen. 
 
Next, we investigated whether MIF produced by B lymphocytes alone is 
sufficient to restore EAE susceptibility in MIF knockout mice.  We hypothesized 
that MIF acts by an autocrine mechanism via B lymphocytes to mediate the 
inflammatory damage seen in EAE and MS.  If MIF does act in an autocrine 
manner as we hypothesized, then B lymphocytes could produce the MIF needed 
for their survival.  Thus, B lymphocytes from a wild-type environment  would be 
predicted to restore EAE susceptibility in a MIF deficient mouse.  Through a 
series of transfers and immunizations, we determined that B lymphocyte 
production of MIF alone is not sufficient for the progression of EAE.  Mice with 
MIF deficient environments and MIF deficient T lymphocytes, but with MIF 
producing B lymphocytes, remained protected from EAE.   
 
We performed another series of experiments to develop mouse models where 
MIF was produced by both T and B lymphocytes.  This model allowed us to 
investigate whether MIF production by T lymphocytes was able to affect B 
lymphocytes and restore EAE susceptibility in an otherwise MIF deficient 
mouse.  Although previous findings with the adoptive transfer experiments 
excluded MIF production by T lymphocytes alone as the source of the relevant 
MIF, this model instead, explores the contribution of T lymphocyte produced 
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MIF to the maturation and proliferation of B lymphocytes.  We observed that 
regardless of MIF production by either B or T lymphocytes, mice with an MIF 
deficient background remained protected from EAE immunization.  This 
allowed us to eliminate the lymphoid lineage of bone marrow derived cells as the 
relevant source of MIF in EAE.   
 
Considering the above results, our data suggests a role of MIF with respect to B 
lymphocytes in EAE and MS.  The recent studies with Rituximab therapy show 
that the depletion of B lymphocytes is significantly beneficial in the treatment of 
MS (Hauser S., 2008).  Additionally, we have previously reported that the absence 
of MIF is protective during the progression of EAE.  Our results have shown 
that the absence of MIF results in fewer mature B lymphocytes and less 
proliferation of the resulting B lymphocyte population.   These observations, 
when taken with the success of B lymphocyte depletion therapies, argue for an 
important function of MIF in the development of B lymphocytes.  Although we 
have shown that B lymphocytes do not mediate inflammation through the 
autocrine production of MIF or via MIF production by T lymphocytes, the effect 
of MIF on B lymphocytes cannot eliminated as an important factor in EAE 
progression.   
 
Another cell may produce the necessary MIF which then acts on B lymphocytes 
to mediate the inflammatory response.  The relevant cellular source of MIF may 
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be a cell that enters the CNS after the BBB is compromised.  Or more likely, due 
to the bone marrow derivation of the relevant cellular source, the pathogenic 
MIF may be produced by a resident CNS cell such as a bone marrow derived 
dendritic cell.  The production of MIF by this cellular source may act on B 
lymphocytes, providing them with the adequate survival signals.    
 
Additionally, the relevant source of MIF may be another bone marrow derived 
cell other than the B lymphocyte.  Unpublished observations from our lab show 
that microglia are modified in an MIF deficient environment.  Microglia are bone 
marrow derived cells and are the resident APCs in the CNS.  In the activated 
state, they can present antigen and phagocytose foreign material.  Primary 
microglial cultures, when exposed to exogenous MIF, elaborate pro-inflammatory 
cytokines, such as IL-6 and iNOS.  Corroborating this observation, the injection 
of MIF into the spinal cord of wild-type mice causes the microglia to adopt an 
activated morphology.  When microglia are not activated and in the ramified 
state, they can move freely about neural tissue but cannot present antigens or 
produce pro-inflammatory cytokines.  However after injection with MIF, the 
microglia show an activated ameboid morphology, indicating they can now 
present antigen, exert cytotoxic effects, and secrete pro-inflammatory cytokines.   
Thus, the production of MIF may be activating microglia to present myelin to T-
lymphocytes and secreting pro-inflammatory cytokines to recruit additional 
immune cells to the CNS.  The antigen presenting abilities of B lymphocytes are 
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more specific and able to process and break down whole protein.  MIF activated 
microglia may initiate the immune response in EAE and MS but then recruit B 
lymphocytes to the site of damage, where they can more effectively activate the 
adaptive immune response.     
 
A second hypothesis for the role of MIF in B lymphocyte maturation involves 
the ability of MIF to upregulate toll-like receptor 4 (TLR4) (Roger, 2001).  
Natural agonists following infection could engage TLRs during the onset of MS.  
Stimulation of TLR4 agonists results in MIF production and once MIF is 
produced, it can mediate the upregulation of TLR4  (Roger, 2001).  Recently, 
TLR4 has been shown to be an accessory stimulus in B cell development by 
complementing the B lymphocyte-activating factor (BAFF) pathway (Hayashi, 
2010).  Ultimately, TLR4 has been implicated in stimulating B cell maturation  
(Hayashi, 2010).  Since MIF is a potent upregulator of TLR4 and MS and EAE 
involve TLR4 agonists, MIF may act via TLR4 to help the BAFF pathway which 
results in B lymphocyte maturation.   In the MIF deficient mouse, TLR4 may not 
be up regulated and thus, B lymphocytes do not receive the appropriate 
maturation signals.  
 
MIF may also mediate B lymphocyte activity through the vascular cell adhesion 
molecule, VCAM-1.  MIF deficient mice down-regulate VCAM-1, an important 
cellular adhesion molecule involved in the diapedesis of lymphocytes into CNS 
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tissue  (Denkinger, 2003).  Interestingly, VCAM-1 is also intricately involved in 
early B lymphocyte maturation.  VCAM-1 is expressed on bone marrow stromal 
cells and binds with the VLA-4 molecule on the surface of pro-B lymphocytes to 
induce expression of the IL-7 receptor.  Expression of IL-7R is an intermediate 
step between pro-B lymphocytes and pre-B lymphocytes.  The absence of MIF 
and down-regulation of VCAM-1 may prevent pro-B lymphocytes from properly 
attaching to the bone marrow stromal cells and receiving the adequate maturation 
signals. 
 
 More research is needed in this area to explore the myeloid lineage of bone 
marrow derived cells to determine the specific source of the pathogenic MIF in 
EAE and MS.   The difference in TLR4 regulation should be explored in the MIF 
deficient environment.  We would expect TLR4 to be down-regulated in an MIF 
deficient mouse relative to a wild-type mouse.  Another future direction would be 
to compare the B lymphocyte population between an MIF deficient mouse and 
wild-type mouse after immunization.  The results thus far have compared B 
lymphocyte populations only in naïve mice.  We would expect these differences 
to be apparent after immunization and possibly, more pronounced.  Lastly, MIF 
production by other bone marrow derived cells should be explored to determine 
their contribution to B lymphocyte maturation and survival in EAE.        
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Answering the above questions has important implications for elucidating the 
effector functions of B lymphocytes which require MIF for maturation.  
Additionally, they may provide direction to better understand the role of MIF in 
inflammation.  This would lead to the development of MIF inhibitors to modify 
B lymphocytes in a variety of inflammatory diseases, autoimmune or not.        
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